Cargando…
Morusflavone, a New Therapeutic Candidate for Prostate Cancer by CYP17A1 Inhibition: Exhibited by Molecular Docking and Dynamics Simulation
Morusflavone, a flavonoid from Morus alba L., was evaluated for its interactive ability and stability with CYP17A1, in comparison with abiraterone, which is a Food and Drug Administration (FDA)-approved CYP17A1 inhibitor. CYP17A1 inhibition is an important therapeutic target for prostate cancer. The...
Autores principales: | Abdi, Sayed Aliul Hasan, Ali, Amena, Sayed, Shabihul Fatma, Ahsan, Mohamed Jawed, Tahir, Abu, Ahmad, Wasim, Shukla, Shatrunajay, Ali, Abuzer |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8468843/ https://www.ncbi.nlm.nih.gov/pubmed/34579444 http://dx.doi.org/10.3390/plants10091912 |
Ejemplares similares
-
Multi-Epitope-Based Vaccine Candidate for Monkeypox: An In Silico Approach
por: Abdi, Sayed Aliul Hasan, et al.
Publicado: (2022) -
Sunscreen Ingredient Octocrylene’s Potency to Disrupt Vitamin D Synthesis
por: Abdi, Sayed Aliul Hasan, et al.
Publicado: (2022) -
Serotonin Receptor agonist and Risk of Paresthesia in Migraine Patients: A Dose-Response Model-Based (Network) Meta-Analysis
por: Hasan Abdi, Sayed Aliul, et al.
Publicado: (2022) -
Ultrasound promoted green synthesis, anticancer evaluation, and molecular docking studies of hydrazines: a pilot trial
por: Ali, Amena, et al.
Publicado: (2021) -
Synthesis, DFT Analyses, Antiproliferative Activity, and Molecular Docking Studies of Curcumin Analogues
por: Ahsan, Mohamed Jawed, et al.
Publicado: (2022)